- Home
- CNTA vs CRGY Comparison
CNTA vs CRGY Comparison
Compare CNTA & CRGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNTA | CRGY |
|---|---|---|
| Founded | 2020 | 1986 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.3B |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CNTA | CRGY |
|---|---|---|
| Price | $28.02 | $13.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $40.89 | $14.00 |
| AVG Volume (30 Days) | 1.2M | ★ 9.6M |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 3.56% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,579,782,000.00 |
| Revenue This Year | N/A | $27.35 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $99.08 |
| Revenue Growth | N/A | ★ 22.14 |
| 52 Week Low | $9.60 | $6.83 |
| 52 Week High | $30.58 | $13.57 |
Technical Indicators
Market Signals| Indicator | CNTA | CRGY |
|---|---|---|
| Relative Strength Index (RSI) | 57.19 | 72.64 |
| Support Level | $24.62 | $8.19 |
| Resistance Level | $30.29 | N/A |
| Average True Range (ATR) | 1.53 | 0.47 |
| MACD | -0.05 | 0.08 |
| Stochastic Oscillator | 71.20 | 98.48 |
Price Performance
Historical ComparisonAbout CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About CRGY Crescent Energy Company
Crescent Energy Co is an energy company committed to delivering value for shareholders through disciplined growth, acquisition ideas, and the consistent return of capital. Its long-life, balanced portfolio combines stable cash flows from low-decline production with deep, high-quality development inventory. The Company's investing and operating activities are focused in Texas and the Rocky Mountain region.